These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17397121)

  • 41. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
    Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
    J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease.
    Onozuka H; Nakajima A; Matsuzaki K; Shin RW; Ogino K; Saigusa D; Tetsu N; Yokosuka A; Sashida Y; Mimaki Y; Yamakuni T; Ohizumi Y
    J Pharmacol Exp Ther; 2008 Sep; 326(3):739-44. PubMed ID: 18544674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oxygen treatment triggers cognitive impairment in Alzheimer's transgenic mice.
    Arendash GW; Cox AA; Mori T; Cracchiolo JR; Hensley KL; Roberts LJ
    Neuroreport; 2009 Aug; 20(12):1087-92. PubMed ID: 19543132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
    Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
    Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alzheimer's and the immune system.
    Young O
    Lab Anim (NY); 2007 Jun; 36(6):8. PubMed ID: 17519932
    [No Abstract]   [Full Text] [Related]  

  • 46. 12th international conference on Alzheimer's disease. Part 1. 11-16 July 2009, Vienna, Austria.
    Filson S
    IDrugs; 2009 Sep; 12(9):535-6. PubMed ID: 19697267
    [No Abstract]   [Full Text] [Related]  

  • 47. Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice.
    Luo F; Seifert TR; Edalji R; Loebbert RW; Hradil VP; Harlan J; Schmidt M; Nimmrich V; Cox BF; Fox GB
    Neuroscience; 2008 Jul; 155(1):263-9. PubMed ID: 18534764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combating Alzheimer's disease with multifunctional molecules designed for metal passivation.
    Schugar H; Green DE; Bowen ML; Scott LE; Storr T; Böhmerle K; Thomas F; Allen DD; Lockman PR; Merkel M; Thompson KH; Orvig C
    Angew Chem Int Ed Engl; 2007; 46(10):1716-8. PubMed ID: 17397084
    [No Abstract]   [Full Text] [Related]  

  • 49. [About mice and men. Not certain that findings in mice with Alzheimer disease can be applied in clinical reality].
    Minthon L
    Lakartidningen; 2006 Dec 6-12; 103(49):3916. PubMed ID: 17212270
    [No Abstract]   [Full Text] [Related]  

  • 50. Alzheimer research forum live discussion: mice on trial? Issues in the design of drug studies.
    J Alzheimers Dis; 2009; 16(1):197-205. PubMed ID: 19158436
    [No Abstract]   [Full Text] [Related]  

  • 51. Alzheimer's disease as copper deficiency.
    Klevay LM
    Med Hypotheses; 2008; 70(4):802-7. PubMed ID: 17928161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease.
    Giovannini MG; Cerbai F; Bellucci A; Melani C; Grossi C; Bartolozzi C; Nosi D; Casamenti F
    Neuroscience; 2008 May; 153(3):618-33. PubMed ID: 18406062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 12th international conference on Alzheimer's disease. Part 2. 11-16 July 2009, Vienna, Austria.
    Filson S
    IDrugs; 2009 Sep; 12(9):537-8. PubMed ID: 19697268
    [No Abstract]   [Full Text] [Related]  

  • 55. Widespread changes in dendritic spines in a model of Alzheimer's disease.
    Knafo S; Alonso-Nanclares L; Gonzalez-Soriano J; Merino-Serrais P; Fernaud-Espinosa I; Ferrer I; DeFelipe J
    Cereb Cortex; 2009 Mar; 19(3):586-92. PubMed ID: 18632740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A breakthrough for research on Alzheimer disease. A model for drug testing].
    Nordstedt C; Näslund J; Tjernberg LO; Terenius L
    Lakartidningen; 1995 May; 92(18):1899-900. PubMed ID: 7746038
    [No Abstract]   [Full Text] [Related]  

  • 57. Alzheimer's theory makes a splash.
    Schnabel J
    Nature; 2009 May; 459(7245):310. PubMed ID: 19458681
    [No Abstract]   [Full Text] [Related]  

  • 58. Therapeutic compliance of nanomedicine in Alzheimer's disease.
    Wilson B
    Nanomedicine (Lond); 2011 Sep; 6(7):1137-9. PubMed ID: 21929451
    [No Abstract]   [Full Text] [Related]  

  • 59. Enantioselective total synthesis and determination of the absolute configuration of the 4,6,8,10,16,18-hexamethyldocosane from Antitrogus parvulus.
    Herber C; Breit B
    Angew Chem Int Ed Engl; 2005 Aug; 44(33):5267-9. PubMed ID: 16035027
    [No Abstract]   [Full Text] [Related]  

  • 60. Transgenic model applications to drug discovery.
    Polites HG
    Int J Exp Pathol; 1996 Dec; 77(6):257-62. PubMed ID: 9155659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.